Form 4 for TSHA Taysha Gene Therapies, Inc.
Accepted 2025-09-12 00:00:00 ET · period of report 2025-09-10 · accession 0001415889-25-024369 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-09-12 | 2025-09-10 | TSHA | Nagendran Sukumar | Pres, Head of R, D, Dir | M - OptEx | $0.7 | +41.1K | 1.21M | +4% | +$28.8K |
| D | 2025-09-12 | 2025-09-10 | TSHA | Nagendran Sukumar | Pres, Head of R, D, Dir | S - Sale+OE | $3.23 | -200.0K | 1.01M | -17% | -$646.0K |
| D | 2025-09-12 | 2025-09-10 | TSHA | Nagendran Sukumar | Pres, Head of R, D, Dir | M - OptEx | $0.00 | -41.1K | 292.9K | -12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-10 | M | A | 41,150 | $0.7 | 1,206,439 | D | — | — | |
| 2 | Common | Common Stock | 2025-09-10 | S | D | 200,000 | $3.23 | 1,006,439 | D | — | — | (F2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.165 to $3.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Employee Stock Option (right to buy) | 2025-09-10 | M | D | 41,150 | $0.00 | 292,855 | D | $0.7 · — to 2033-12-14 | 41,150 Common Stock | (F3) The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. |